ODD
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
April 15, 2024Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
FDA grants ODD to Revolo Biotherapeutics’ eosinophilic esophagitis treatment
February 1, 2024Medical Communications FDA, ODD, Pharmacy, Revolo Biotherapeutics, eosinophilic esophagitis
Revolo Biotherapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, …
Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment
November 28, 2023Research and Development Arcturus Therapeutics, Chronic Diseases, FDA, ODD, cystic fibrosis
Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …
FDA gives Orphan Drug Designation to Faron Pharmaceuticals’ Bexmarilimab
August 29, 2023Research and Development FDA, Faron, ODD, Oncology, leukemia
Faron Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its …
FDA grants ODD to NXC-201 as multiple myeloma treatment
August 24, 2023Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma
Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …
FDA grants orphan drug designation to Genprex’s Reqorsa
August 15, 2023Medical Communications FDA, ODD, Oncology, Reqorsa
Gene therapy company Genprex has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) …
